FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2189897946> ?p ?o ?g. }

• W2189897946 endingPage "e0144559" @default.
• W2189897946 startingPage "e0144559" @default.
• W2189897946 abstract "Background We have harnessed a novel biological system, the bacterial minicell, to deliver cancer therapeutics to cancer cells. Preclinical studies showed that epidermal growth factor receptor (EGFR)-targeted, paclitaxel-loaded minicells (EGFRminicellsPac) have antitumor effects in xenograft models. To examine the safety of the minicell delivery system, we initiated a first-time-in-human, open-label, phase I clinical study of EGFRminicellsPac in patients with advanced solid tumors. Methodology Patients received 5 weekly infusions followed by a treatment free week. Seven dose levels (1x108, 1x109, 3x109, 1x1010, 1.5x1010, 2x1010, 5x1010) were evaluated using a 3+3 dose-escalation design. Primary objectives were safety, tolerability and determination of the maximum tolerated dose. Secondary objectives were assessment of immune/inflammatory responses and antitumor activity. Principal Findings Twenty eight patients were enrolled, 22 patients completed at least one cycle of EGFRminicellsPac; 6 patients did not complete a cycle due to rapidly progressive disease. A total of 236 doses was delivered over 42 cycles, with a maximum of 45 doses administered to a single patient. Most common treatment-related adverse events were rigors and pyrexia. No deaths resulted from treatment-related adverse events and the maximum tolerated dose was defined as 1x1010 EGFRminicellsPac. Surprisingly, only a mild self-limiting elevation in the inflammatory cytokines IL-6, IL-8 and TNFα and anti-inflammatory IL-10 was observed. Anti-LPS antibody titers peaked by dose 3 and were maintained at that level despite repeat dosing with the bacterially derived minicells. Ten patients (45%; n = 22) achieved stable disease as their best response. Conclusions/Significance This is the first study in humans of a novel biological system that can provide targeted delivery of a range of chemotherapeutic drugs to solid tumor cells. Bispecific antibody-targeted minicells, packaged with the chemotherapeutic paclitaxel, were shown to be safe in patients with advanced solid tumors with modest clinical efficacy observed. Further study in Phase II trials is planned. Trial Registration Australian New Zealand Clinical Trials Registry ACTRN12609000672257" @default.
• W2189897946 created "2016-06-24" @default.
• W2189897946 creator A5020515172 @default.
• W2189897946 creator A5024726678 @default.
• W2189897946 creator A5028926236 @default.
• W2189897946 creator A5045959942 @default.
• W2189897946 creator A5052670897 @default.
• W2189897946 creator A5078038970 @default.
• W2189897946 creator A5078312966 @default.
• W2189897946 creator A5087036316 @default.
• W2189897946 creator A5091652642 @default.
• W2189897946 date "2015-12-11" @default.
• W2189897946 modified "2023-10-17" @default.
• W2189897946 title "A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells" @default.
• W2189897946 cites W1483444028 @default.
• W2189897946 cites W1570441204 @default.
• W2189897946 cites W1871308790 @default.
• W2189897946 cites W1983718760 @default.
• W2189897946 cites W1985858988 @default.
• W2189897946 cites W2003659611 @default.
• W2189897946 cites W2004465286 @default.
• W2189897946 cites W2013470095 @default.
• W2189897946 cites W2025036947 @default.
• W2189897946 cites W2036254354 @default.
• W2189897946 cites W2072024015 @default.
• W2189897946 cites W2082133979 @default.
• W2189897946 cites W2096720114 @default.
• W2189897946 cites W2142564546 @default.
• W2189897946 cites W2149684470 @default.
• W2189897946 cites W2151191049 @default.
• W2189897946 cites W2166609912 @default.
• W2189897946 cites W2191654227 @default.
• W2189897946 doi "https://doi.org/10.1371/journal.pone.0144559" @default.
• W2189897946 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4699457" @default.
• W2189897946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26659127" @default.
• W2189897946 hasPublicationYear "2015" @default.
• W2189897946 type Work @default.
• W2189897946 sameAs 2189897946 @default.
• W2189897946 citedByCount "46" @default.
• W2189897946 countsByYear W21898979462016 @default.
• W2189897946 countsByYear W21898979462017 @default.
• W2189897946 countsByYear W21898979462018 @default.
• W2189897946 countsByYear W21898979462019 @default.
• W2189897946 countsByYear W21898979462020 @default.
• W2189897946 countsByYear W21898979462021 @default.
• W2189897946 countsByYear W21898979462022 @default.
• W2189897946 countsByYear W21898979462023 @default.
• W2189897946 crossrefType "journal-article" @default.
• W2189897946 hasAuthorship W2189897946A5020515172 @default.
• W2189897946 hasAuthorship W2189897946A5024726678 @default.
• W2189897946 hasAuthorship W2189897946A5028926236 @default.
• W2189897946 hasAuthorship W2189897946A5045959942 @default.
• W2189897946 hasAuthorship W2189897946A5052670897 @default.
• W2189897946 hasAuthorship W2189897946A5078038970 @default.
• W2189897946 hasAuthorship W2189897946A5078312966 @default.
• W2189897946 hasAuthorship W2189897946A5087036316 @default.
• W2189897946 hasAuthorship W2189897946A5091652642 @default.
• W2189897946 hasBestOaLocation W21898979461 @default.
• W2189897946 hasConcept C121608353 @default.
• W2189897946 hasConcept C126322002 @default.
• W2189897946 hasConcept C143998085 @default.
• W2189897946 hasConcept C159654299 @default.
• W2189897946 hasConcept C197934379 @default.
• W2189897946 hasConcept C203014093 @default.
• W2189897946 hasConcept C2777288759 @default.
• W2189897946 hasConcept C2778375690 @default.
• W2189897946 hasConcept C535046627 @default.
• W2189897946 hasConcept C71924100 @default.
• W2189897946 hasConcept C8891405 @default.
• W2189897946 hasConcept C90924648 @default.
• W2189897946 hasConcept C98274493 @default.
• W2189897946 hasConceptScore W2189897946C121608353 @default.
• W2189897946 hasConceptScore W2189897946C126322002 @default.
• W2189897946 hasConceptScore W2189897946C143998085 @default.
• W2189897946 hasConceptScore W2189897946C159654299 @default.
• W2189897946 hasConceptScore W2189897946C197934379 @default.
• W2189897946 hasConceptScore W2189897946C203014093 @default.
• W2189897946 hasConceptScore W2189897946C2777288759 @default.
• W2189897946 hasConceptScore W2189897946C2778375690 @default.
• W2189897946 hasConceptScore W2189897946C535046627 @default.
• W2189897946 hasConceptScore W2189897946C71924100 @default.
• W2189897946 hasConceptScore W2189897946C8891405 @default.
• W2189897946 hasConceptScore W2189897946C90924648 @default.
• W2189897946 hasConceptScore W2189897946C98274493 @default.
• W2189897946 hasIssue "12" @default.
• W2189897946 hasLocation W21898979461 @default.
• W2189897946 hasLocation W21898979462 @default.
• W2189897946 hasLocation W21898979463 @default.
• W2189897946 hasLocation W21898979464 @default.
• W2189897946 hasLocation W21898979465 @default.
• W2189897946 hasLocation W21898979466 @default.
• W2189897946 hasLocation W21898979467 @default.
• W2189897946 hasOpenAccess W2189897946 @default.
• W2189897946 hasPrimaryLocation W21898979461 @default.
• W2189897946 hasRelatedWork W1988492690 @default.
• W2189897946 hasRelatedWork W2010675100 @default.
• W2189897946 hasRelatedWork W2029413469 @default.
• W2189897946 hasRelatedWork W2087016115 @default.

• next